DNA Repair and Prostate Cancer: A Field Ripe for Harvest

Alan H. Bryce, Oliver Sartor, Johann de Bono

Research output: Contribution to journalEditorialpeer-review

5 Scopus citations

Abstract

Recent data have revealed antitumor activity for four PARP inhibitors, two of which (olaparib and rucaparib) are approved by the US Food and Drug Administration for metastatic castrate-resistant prostate cancer with selected DNA repair defects. Additional clinical trials are in progress for talazoparib, veliparib, and niraparib. More progress can be anticipated in the near future.

Original languageEnglish (US)
Pages (from-to)486-488
Number of pages3
JournalEuropean urology
Volume78
Issue number4
DOIs
StatePublished - Oct 2020

ASJC Scopus subject areas

  • Urology

Fingerprint Dive into the research topics of 'DNA Repair and Prostate Cancer: A Field Ripe for Harvest'. Together they form a unique fingerprint.

Cite this